Results from a Phase 2 clinical trial, CoDIFy, evaluating Summit Therapeutics' (SMMT -0.7%) now-lead candidate ridinilazole for the prevention of recurrence of infection from Clostridium difficile (C. diff), showed a substantial treatment advantage versus vancomycin. The results were just published in PLOS ONE.
Treatment with ridinilazole, an orally available small molecule antibiotic, resulted in a 59% reduction in recurrence versus vancomycin (14.3% vs. 34.8%).
Phase 3 development should commence next year.
Previously: Summit's ridinilazole beats vancomycin in mid-stage C. diff study (Nov. 23, 2015)
Subscribe for full text news in your inbox